{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:52:55Z","timestamp":1792212775670,"version":"4.4.0"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T00:00:00Z","timestamp":1638835200000},"content-version":"vor","delay-in-days":1540,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Human induced pluripotent stem cells (hiPSC) hold great promise in diagnostic and therapeutic applications. However, translation of hiPSC technology depends upon a means of assessing hiPSC quality that is quantitative, high-throughput, and can decipher malignant teratocarcinoma clones from normal cell lines. These attributes are lacking in current approaches such as detection of cell surface makers, RNA profiling, and\/or teratoma formation assays. The latter remains the gold standard for assessing clone quality in hiPSCs, but is expensive, time-consuming, and incompatible with high-throughput platforms. Herein, we describe a novel method for determining hiPSC quality that exploits pluripotent cells\u2019 documented hypersensitivity to the topoisomerase inhibitor etoposide (CAS No. 33419-42-0). Based on a study of 115 unique hiPSC clones, we established that a half maximal effective concentration (EC50) value of &amp;lt;300 nM following 24 hours of exposure to etoposide demonstrated a positive correlation with RNA profiles and colony morphology metrics associated with high quality hiPSC clones. Moreover, our etoposide sensitivity assay (ESA) detected differences associated with culture maintenance, and successfully distinguished malignant from normal pluripotent clones independent of cellular morphology. Overall, the ESA provides a simple, straightforward method to establish hiPSC quality in a quantitative and functional assay capable of being incorporated into a generalized method for establishing a quality control standard for all types of pluripotent stem cells.<\/jats:p>","DOI":"10.1002\/sctm.17-0116","type":"journal-article","created":{"date-parts":[[2017,9,19]],"date-time":"2017-09-19T07:02:56Z","timestamp":1505804576000},"page":"1829-1839","source":"Crossref","is-referenced-by-count":7,"title":["Quantification of Etoposide Hypersensitivity: A Sensitive, Functional Method for Assessing Pluripotent Stem Cell Quality"],"prefix":"10.1093","volume":"6","author":[{"given":"Frank J.","family":"Secreto","sequence":"first","affiliation":[{"name":"a Program for Hypoplastic Left Heart Syndrome-Center for Regenerative Medicine, Mayo Clinic, Rochester, Minnesota, USA"},{"name":"b Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Li","sequence":"additional","affiliation":[{"name":"a Program for Hypoplastic Left Heart Syndrome-Center for Regenerative Medicine, Mayo Clinic, Rochester, Minnesota, USA"},{"name":"c Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyson J.","family":"Smith","sequence":"additional","affiliation":[{"name":"a Program for Hypoplastic Left Heart Syndrome-Center for Regenerative Medicine, Mayo Clinic, Rochester, Minnesota, USA"},{"name":"b Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth S.","family":"Bruinsma","sequence":"additional","affiliation":[{"name":"a Program for Hypoplastic Left Heart Syndrome-Center for Regenerative Medicine, Mayo Clinic, Rochester, Minnesota, USA"},{"name":"b Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Perales-Clemente","sequence":"additional","affiliation":[{"name":"a Program for Hypoplastic Left Heart Syndrome-Center for Regenerative Medicine, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saji","family":"Oommen","sequence":"additional","affiliation":[{"name":"a Program for Hypoplastic Left Heart Syndrome-Center for Regenerative Medicine, Mayo Clinic, Rochester, Minnesota, USA"},{"name":"b Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gresin","family":"Hawse","sequence":"additional","affiliation":[{"name":"a Program for Hypoplastic Left Heart Syndrome-Center for Regenerative Medicine, Mayo Clinic, Rochester, Minnesota, USA"},{"name":"b Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sybil C. L.","family":"Hrstka","sequence":"additional","affiliation":[{"name":"a Program for Hypoplastic Left Heart Syndrome-Center for Regenerative Medicine, Mayo Clinic, Rochester, Minnesota, USA"},{"name":"b Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie K.","family":"Arendt","sequence":"additional","affiliation":[{"name":"a Program for Hypoplastic Left Heart Syndrome-Center for Regenerative Medicine, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma B.","family":"Brandt","sequence":"additional","affiliation":[{"name":"a Program for Hypoplastic Left Heart Syndrome-Center for Regenerative Medicine, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis A.","family":"Wigle","sequence":"additional","affiliation":[{"name":"d Division of Thoracic Surgery, Mayo Clinic, Rochester, Minnesota, USA"},{"name":"e Center for Regenerative Medicine BioTrust, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Nelson","sequence":"additional","affiliation":[{"name":"a Program for Hypoplastic Left Heart Syndrome-Center for Regenerative Medicine, Mayo Clinic, Rochester, Minnesota, USA"},{"name":"b Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA"},{"name":"f Transplant Center, Mayo Clinic, Rochester, Minnesota, USA"},{"name":"g Division of Pediatric Cardiology, Mayo Clinic, Rochester, Minnesota, USA"},{"name":"h Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,9,19]]},"reference":[{"key":"2021122706065143300_R1","doi-asserted-by":"crossref","first-page":"500","DOI":"10.5966\/sctm.2013-0162","article-title":"Concise review: Drug discovery in the age of the induced pluripotent stem cell","volume":"3","author":"Ko","year":"2014","journal-title":"Stem Cells Translational Medicine"},{"key":"2021122706065143300_R2","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/534310a","article-title":"How iPS cells changed the world","volume":"534","author":"Scudellari","year":"2016","journal-title":"Nature"},{"key":"2021122706065143300_R3","article-title":"Induced pluripotent stem cells: Competitive analysis of the U.S. Patent landscape","author":"Hildreth","year":"2015","journal-title":"Bioinformant"},{"key":"2021122706065143300_R4","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/glycob\/cwu012","article-title":"Evidences for the involvement of cell surface glycans in stem cell pluripotency and differentiation","volume":"24","author":"Alisson-Silva","year":"2014","journal-title":"Glycobiology"},{"key":"2021122706065143300_R5","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nmeth.1580","article-title":"A bioinformatic assay for pluripotency in human cells","volume":"8","author":"Muller","year":"2011","journal-title":"Nat Methods"},{"key":"2021122706065143300_R6","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.stemcr.2015.05.006","article-title":"TeratoScore: Assessing the differentiation potential of human pluripotent stem cells by quantitative expression analysis of teratomas","volume":"4","author":"Avior","year":"2015","journal-title":"Stem Cell Reports"},{"key":"2021122706065143300_R7","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.stem.2008.11.008","article-title":"Guidelines and techniques for the generation of induced pluripotent stem cells","volume":"3","author":"Maherali","year":"2008","journal-title":"Cell Stem Cell"},{"key":"2021122706065143300_R8","doi-asserted-by":"crossref","first-page":"34009","DOI":"10.1038\/srep34009","article-title":"Parametric analysis of colony morphology of non-labelled live human pluripotent stem cells for cell quality control","volume":"6","author":"Kato","year":"2016","journal-title":"Sci Rep"},{"key":"2021122706065143300_R9","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0960-9822(98)70061-2","article-title":"ES cells do not activate p53-dependent stress responses and undergo p53-independent apoptosis in response to DNA damage","volume":"8","author":"Aladjem","year":"1998","journal-title":"Curr Biol"},{"key":"2021122706065143300_R10","doi-asserted-by":"crossref","first-page":"e13410","DOI":"10.1371\/journal.pone.0013410","article-title":"DNA damage responses in human induced pluripotent stem cells and embryonic stem cells","volume":"5","author":"Momcilovic","year":"2010","journal-title":"PLoS One"},{"key":"2021122706065143300_R11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1667\/RR14417.1","article-title":"Pluripotent stem cells and DNA damage response to ionizing radiations","volume":"186","author":"Mujoo","year":"2016","journal-title":"Radiat Res"},{"key":"2021122706065143300_R12","first-page":"576","article-title":"DNA damage response in neonatal and adult stromal cells compared with induced pluripotent stem cells. Stem Cells","volume":"4","author":"Liedtke","year":"2015","journal-title":"Translational Medicine"},{"key":"2021122706065143300_R13","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nm.2304","article-title":"The cancer stem cell: Premises, promises and challenges","volume":"17","author":"Clevers","year":"2011","journal-title":"Nat Med"},{"key":"2021122706065143300_R14","doi-asserted-by":"crossref","first-page":"13560","DOI":"10.1016\/S0021-9258(18)90729-5","article-title":"Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II","volume":"259","author":"Chen","year":"1984","journal-title":"J Biol Chem"},{"key":"2021122706065143300_R15","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0006-291X(84)90454-6","article-title":"Inhibition of the DNA catenation activity of type II topoisomerase by VP16\u2013213 and VM26","volume":"122","author":"Minocha","year":"1984","journal-title":"Biochem Biophys Res Commun"},{"key":"2021122706065143300_R16","first-page":"5857","article-title":"Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage","volume":"44","author":"Ross","year":"1984","journal-title":"Cancer Res."},{"key":"2021122706065143300_R17","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/S0959-8049(98)00228-7","article-title":"Etoposide: Four decades of development of a topoisomerase II inhibitor","volume":"34","author":"Hande","year":"1998","journal-title":"Eur J Cancer"},{"key":"2021122706065143300_R18","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.scr.2007.10.003","article-title":"p53 is required for etoposide-induced apoptosis of human embryonic stem cells","volume":"1","author":"Grandela","year":"2007","journal-title":"Stem Cell Res"},{"key":"2021122706065143300_R19","first-page":"709","article-title":"Apoptotic susceptibility to DNA damage of pluripotent stem cells facilitates pharmacologic purging of teratoma risk. Stem Cells","volume":"1","author":"Smith","year":"2012","journal-title":"Translational Medicine"},{"key":"2021122706065143300_R20","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.4161\/cc.10.12.16006","article-title":"Sensitivity of human embryonic and induced pluripotent stem cells to a topoisomerase II poison etoposide","volume":"10","author":"Velichko","year":"2011","journal-title":"Cell Cycle"},{"key":"2021122706065143300_R21","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/stem.1389","article-title":"Disease-causing mitochondrial heteroplasmy segregated within induced pluripotent stem cell clones derived from A MELAS patient","volume":"31","author":"Folmes","year":"2013","journal-title":"Stem Cells"},{"key":"2021122706065143300_R22","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/ijc.2910290507","article-title":"Cell-surface antigens of a clonal human embryonal carcinoma cell line: Morphological and antigenic differentiation in culture","volume":"29","author":"Andrews","year":"1982","journal-title":"Int J Cancer"},{"key":"2021122706065143300_R23","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1089\/hyb.1984.3.347","article-title":"Three monoclonal antibodies defining distinct differentiation antigens associated with different high molecular weight polypeptides on the surface of human embryonal carcinoma cells","volume":"3","author":"Andrews","year":"1984","journal-title":"Hybridoma"},{"key":"2021122706065143300_R24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s12015-013-9487-7","article-title":"The current status of iPS cells in cardiac research and their potential for tissue engineering and regenerative medicine","volume":"10","author":"Martins","year":"2014","journal-title":"Stem Cell Rev"},{"key":"2021122706065143300_R25","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/nbt.3387","article-title":"A qPCR ScoreCard quantifies the differentiation potential of human pluripotent stem cells","volume":"33","author":"Tsankov","year":"2015","journal-title":"Nat Biotech"},{"key":"2021122706065143300_R26","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.cell.2010.12.032","article-title":"Reference maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines","volume":"144","author":"Bock","year":"2011","journal-title":"Cell"},{"key":"2021122706065143300_R27","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/jnci\/52.3.921","article-title":"Heterotransplantation of human malignant tumors in \u201cnude\u201d thymusless mice. II. Malignant tumors induced by injection of cell cultures derived from human solid tumors","volume":"52","author":"Giovanella","year":"1974","journal-title":"J Natl Cancer Inst"},{"key":"2021122706065143300_R28","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1432-0436.1990.tb00438.x","article-title":"Alterations of cellular characteristics of a human ovarian teratocarcinoma cell line after in vitro treatment with retinoids","volume":"43","author":"Taylor","year":"1990","journal-title":"Differentiation"},{"key":"2021122706065143300_R29","first-page":"220","article-title":"Retinoic acid-induced differentiation of the developmentally pluripotent human germ cell tumor-derived cell line, NCCIT","volume":"68","author":"Damjanov","year":"1993","journal-title":"Lab Invest"},{"key":"2021122706065143300_R30","first-page":"397","article-title":"[The induction and differentiation of a human teratocarcinoma cell line (PA-1) in vitro]","volume":"28","author":"Xia","year":"1995","journal-title":"Shi Yan Sheng Wu Xue Bao"},{"key":"2021122706065143300_R31","first-page":"147","article-title":"Pluripotent embryonal carcinoma clones derived from the human teratocarcinoma cell line Tera-2. Differentiation in vivo and in vitro","volume":"50","author":"Andrews","year":"1984","journal-title":"Lab Invest"},{"key":"2021122706065143300_R32","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0012-1606(84)90316-6","article-title":"Retinoic acid induces neuronal differentiation of a cloned human embryonal carcinoma cell line in vitro","volume":"103","author":"Andrews","year":"1984","journal-title":"Dev Biol"},{"key":"2021122706065143300_R33","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2605.1987.tb00171.x","article-title":"Cell lines of human germinal cancer","volume":"10","author":"Casper","year":"1987","journal-title":"Int J Androl"},{"key":"2021122706065143300_R34","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/jnci\/53.5.1341","article-title":"Characterization of a cell line from human transitional cell cancer of the urinary tract","volume":"53","author":"Elliott","year":"1974","journal-title":"J Natl Cancer Inst"},{"key":"2021122706065143300_R35","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1432-0436.1988.tb00798.x","article-title":"Activation of four homeobox gene clusters in human embryonal carcinoma cells induced to differentiate by retinoic acid","volume":"37","author":"Mavilio","year":"1988","journal-title":"Differentiation"},{"key":"2021122706065143300_R36","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-1647-4","volume-title":"Human Tumor Cells In Vitro","author":"Fogh","year":"1975"},{"key":"2021122706065143300_R37","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1093\/carcin\/20.10.1899","article-title":"Alterations of SAG mRNA in human cancer cell lines: Requirement for the RING finger domain for apoptosis protection","volume":"20","author":"Sun","year":"1999","journal-title":"Carcinogenesis"},{"key":"2021122706065143300_R38","first-page":"796","article-title":"Nonrandom abnormalities in chromosome 1 in human testicular cancers","volume":"40","author":"Wang","year":"1980","journal-title":"Cancer Res"},{"key":"2021122706065143300_R39","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/nmeth.2999","article-title":"Chemically defined generation of human cardiomyocytes","volume":"11","author":"Burridge","year":"2014","journal-title":"Nat Methods"},{"key":"2021122706065143300_R40","doi-asserted-by":"crossref","DOI":"10.1002\/0471142905.hg2103s87","volume-title":"Chemically defined culture and cardiomyocyte differentiation of human pluripotent stem cells","author":"Burridge","year":"2015"},{"key":"2021122706065143300_R41","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/7651_2014_118","article-title":"The suspension culture of undifferentiated human pluripotent stem cells using spinner flasks","volume":"1283","author":"Chen","year":"2015","journal-title":"Methods Mol Biol"},{"key":"2021122706065143300_R42","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.15252\/embj.201694892","article-title":"Natural underlying mtDNA heteroplasmy as a potential source of intra-person hiPSC variability","volume":"35","author":"Perales-Clemente","year":"2016","journal-title":"EMBO J"},{"key":"2021122706065143300_R43","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1002\/stem.1734","article-title":"Selection via pluripotency-related transcriptional screen minimizes the influence of somatic origin on iPSC differentiation propensity","volume":"32","author":"Hartjes","year":"2014","journal-title":"Stem Cells"},{"key":"2021122706065143300_R44","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/nrd4738","article-title":"Current status of pluripotent stem cells: Moving the first therapies to the clinic","volume":"14","author":"Kimbrel","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"2021122706065143300_R45","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/wdev.219","article-title":"Teratoma: From spontaneous tumors to the pluripotency\/malignancy assay","volume":"5","author":"Bulic-Jakus","year":"2016","journal-title":"Wiley Interdiscip Rev Dev Biol"},{"key":"2021122706065143300_R46","doi-asserted-by":"crossref","first-page":"e0118670","DOI":"10.1371\/journal.pone.0118670","article-title":"Activin-A and Bmp4 levels modulate cell type specification during CHIR-induced cardiomyogenesis","volume":"10","author":"Kim","year":"2015","journal-title":"PLoS One"},{"key":"2021122706065143300_R47","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1042\/BJ20101707","article-title":"Cardiomyocyte differentiation of pluripotent stem cells and their use as cardiac disease models","volume":"434","author":"Dambrot","year":"2011","journal-title":"Biochem J"},{"key":"2021122706065143300_R48","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.stemcr.2017.03.011","article-title":"High-throughput and cost-effective characterization of induced pluripotent stem cells","volume":"8","author":"D'Antonio","year":"2017","journal-title":"Stem Cell Reports"}],"container-title":["Stem Cells Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fsctm.17-0116","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/6\/10\/1829\/41895043\/stcltm_6_10_1829.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/6\/10\/1829\/41895043\/stcltm_6_10_1829.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T02:47:52Z","timestamp":1642560472000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stcltm\/article\/6\/10\/1829-1839\/6454782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,19]]},"references-count":48,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2017,9,19]]},"published-print":{"date-parts":[[2017,10,1]]}},"URL":"https:\/\/doi.org\/10.1002\/sctm.17-0116","relation":{},"ISSN":["2157-6564","2157-6580"],"issn-type":[{"value":"2157-6564","type":"print"},{"value":"2157-6580","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,10,1]]},"published":{"date-parts":[[2017,9,19]]}}}